Form 4: uniQure CEO Sells Shares Under Pre-Arranged 10b5-1 Plan
Insider Transaction Report
uniQure N.V. CEO Matthew C. Kapusta executed significant stock option exercises and subsequent sales of ordinary shares totaling 296,316 shares under a pre-arranged 10b5-1 plan.
Summary
- Matthew C. Kapusta, CEO and Managing Director of uniQure N.V., reported transactions involving the exercise of stock options and the sale of ordinary shares.
- All reported transactions occurred on September 24, 2025, and were executed under a Rule 10b5-1 sales plan adopted on January 28, 2025.
- Kapusta exercised options to acquire 51,316 ordinary shares at $7.53 per share and 175,000 ordinary shares at $6.22 per share.
- Concurrently, he sold a total of 296,316 ordinary shares in multiple transactions.
- The sales were executed at weighted average prices ranging from $39.59 to $45.10 per share.
- Following these transactions, Kapusta's direct beneficial ownership of ordinary shares is 651,454.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be viewed negatively, these transactions were pre-planned under a 10b5-1 plan, indicating a structured approach to liquidity rather than a reaction to adverse company news. The significant profit realized from option exercises also reflects positively on the company's stock performance.
Positives
- The CEO exercised stock options at significantly lower prices ($7.53 and $6.22) and sold shares at much higher prices (ranging from $39.59 to $45.10), indicating substantial personal profit.
- The transactions were conducted under a pre-arranged Rule 10b5-1 plan, which suggests a planned approach to managing personal holdings rather than a reaction to immediate company news.
Negatives
- Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by investors as it reduces the insider's direct equity stake in the company.
Risks
- Potential negative investor sentiment if the market interprets the insider selling as a lack of confidence, despite the 10b5-1 plan.
Stakeholder Impact
- Shareholders may observe the CEO's reduction in direct equity holdings, which could influence their perception of insider confidence, although the 10b5-1 plan mitigates immediate concerns.
Key Dates
| Date | Description |
|---|---|
| 09/29/2017 | Vesting start date for a stock option (25% vested, then 6.25% quarterly thereafter). |
| 03/14/2018 | Vesting start date for a stock option (25% vested, then 6.25% quarterly thereafter). |
| 02/19/2020 | Adjustment date for previous exercise and sale of 7,501 option shares under a 10b5-1 plan. |
| 01/28/2025 | Date the Rule 10b5-1 sales plan was adopted by the Reporting Person. |
| 09/24/2025 | Date of reported stock option exercises and share sales. |
| 09/26/2025 | Signature date of the filing by Christian Klemt, Attorney-in-Fact. |
| 09/29/2026 | Expiration date for a stock option with an exercise price of $7.53. |
| 03/14/2027 | Expiration date for a stock option with an exercise price of $6.22. |
Keywords
uniQure, QURE, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Matthew C. Kapusta, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.